ABSTRACT
Coronavirus disease is a serious viral infection that is characterized by severe inflammation and lymphopenia. The virus attacks many organs causing acute respiratory distress and malfunctioning of the organs leading to death. Through strengthening of the innate immune system, a balanced diet plays a critical role in defense against bacterial and viral diseases. A healthy diet before, during and after an infection can lessen the severity of the symptoms and speed up the recovery of damaged cells. Due to the Mediterranean diet's high concentration of bioactive polyphenols, which have antioxidant, anti-inflammatory, and antithrombic properties, numerous studies have suggested that it is a preventative dietary strategy against many diseases including coronavirus disease. Nutrition and herbal plants play a key role to enhance the immunity of people to protect and fight against coronavirus. Diet rich in antioxidants and phytochemicals represents perfect barrier to the virus through elevation of the innate immunity of the body. In addition, gut microbiota including prebiotics, probiotics, and synbiotics were found to enhance immunity to reduce the symptoms of the disease during infection. Protein-rich foods and honey bee products reported significant role during and post-coronavirus infection. This review presents updated information from original pre-clinical and clinical researches, and review articles as well to expose the nutritive strategies including breastfeeding benefits to infants pre-infection, during, and post-infection with coronavirus.Copyright © 2023, Scientific Foundation SPIROSKI. All rights reserved.
ABSTRACT
Background: Coronavirus disease-2019 (COVID-19) has caused a pandemic that has recently affected every aspect of life. Fortunately, many vaccines with high safety and efficacy profiles were developed timely to face this pandemic. In a very short time, billions of people were vaccinated. In the meantime, a wide range of neurological syndromes are being reported. Guillain-Barre syndrome (GBS) which is a rare immune-mediated post-infectious peripheral neuropathy was reported after both the COVID-19 infection itself and many types of its vaccines. Method(s): We are reporting a case of post-AstraZeneca vaccine GBS and reviewing the literature of all reported post-COVID-19 vaccines GBS till July 2021. Result(s): 29 adult patients were reported. Of them 58.6% were males. Their mean age is 58.2 years. The median time to clinical onset after vaccine administration was 13.2 days. 86.2% of patients had their symptoms following immunization with the 1st dose of AstraZeneca vector-based covid vaccine. Facial palsy was the most predominant single symptom in 75.8% of patients. Conclusion(s): Guillain-Barre syndrome is a well-recognized but still rare adverse event following vaccination against COVID-19. Although preliminary data incriminates viral vector-based vaccines more than the other types, active post-vaccination surveillance and more powerful statistics are mandatory to reach a solid conclusion regarding the presence of a causal relation.Copyright © 2022
ABSTRACT
Background: Despite the perceived safety and efficacy of COVID-19 vaccines, many reports worldwide highlighted the development of many complications involving CNS. Ischemia, new onset demyelination, and exacerbation of preexisting demyelinating conditions were among the most reported ones. The aim of this study is to report a series of Egyptian patients who developed either first episode of CNS ischemia, demyelination, or exacerbation of a preexisting demyelinating condition after receiving one of the approved COVID-19 vaccines. Material(s) and Method(s): Prospective collection of cases presenting with different CNS complications in temporal association with receiving one of the approved COVID vaccines in the period between December 2021 and March 2022. All patients presented for consultation at Alexandria University Neuroimmunology unit. Result(s): We identified 8 cases with post- vaccine CNS complications. There were 5 females and 3 males, and their ages ranged from 24-60 years. Their symptoms developed after an interval ranging from 3 days up to 4 weeks after the first (n= 3) or second dose of vaccine (n=5). All except one patient were diagnosed as either new onset MS or exacerbation of a preexisting MS. The last case was diagnosed as spinal cord infarction. Conclusion(s): This series adds to the growing literature of the possible association between COVID-19 vaccines and development/ exacerbation of CNS demyelination or ischemia. More data with long-term follow up is needed to establish or refute the causal relationship but meanwhile counseling patients without discouraging vaccination is advised.Copyright © 2022